An observational study in Exocrine Pancreatic Insufficiency, sponsored by Hospital Clinico Universitario de Santiago. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-22.
Sponsored by Hospital Clinico Universitario de Santiago · Observational
EURO-PEI is a multicentre, observational registry conducted at eight specialist pancreatic centres in Spain, Hungary, France, Italy, and the United Kingdom. The registry was designed to capture routine specialist practice without protocol-mandated diagnostic testing, PERT dosing, proton pump inhibitor (PPI) use, or follow-up intervals. Adults aged 18 years or older are eligible if they have a clinician-established diagnosis of PEI and PERT is initiated or actively managed during specialist follow-up. Patients already receiving PERT at registry inclusion, including those entered from any pre-existing database, are eligible if the diagnosis of PEI and the indication for ongoing treatment are confirmed by the treating specialist. Patients may have acute pancreatitis, chronic pancreatitis, cystic fibrosis, pancreatic cancer, pancreatectomy, or other pancreatic or extrapancreatic conditions potentially leading to PEI.
128 studies on the registry are indexed under Exocrine Pancreatic Insufficiency; 27 are open to participants now.
This study's enrollment of 1,015 is above the median of 115 across 35 observational studies indexed under Exocrine Pancreatic Insufficiency.
Browse Exocrine Pancreatic Insufficiency studies →Hospital Clinico Universitario de Santiago is the lead sponsor of 33 studies on the registry; 11 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult patients diagnosed with pancreatic exocrine insufficiency of any etiology.
Exclusion Criteria:
Adult patients diagnosed with pancreatic exocrine insufficiency secondary to chronic pancreatitis, pancreatic cancer, pancreatectomy, acute pancreatitis, and other stiologies.
Drug: Pancreatic Enzyme
Registry of pancreatic enzyme therapy prescribed to included patients
Dose of oral pancreatic enzymes
Dose required for symptoms relief and normalization of the nutritional status
Time frame: Six months
Plan to share: Yes — The data that support the findings of this study are available from the corresponding author upon reasonable request.
Supporting information: Study protocol, Sap, Icf, Csr
No publications or documents are linked to this record.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Exocrine Pancreatic Insufficiency→
Hospital Clinico Universitario de Santiago